Mosanna reports positive Phase 1 results for MOS118
MOS118 was safe and well tolerated across all dose cohorts with no serious adverse events, supporting progression into patients with OSA.
See the latest news and media coverage for Mosanna. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing drug treatments for obstructive sleep apnea
mosanna.comLast updated
In short: Mosanna Therapeutics reported positive Phase 1 results for MOS118, supporting progression into patients with OSA.
MOS118 was safe and well tolerated across all dose cohorts with no serious adverse events, supporting progression into patients with OSA.
The company is developing MOS118, a nighttime nasal spray for obstructive sleep apnea, and appoints David Weber as CEO.
Mosanna Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a locally acting pharmacologic treatment for obstructive sleep apnea (OSA), today announced results from its Phase 1...
REDWOOD CITY, Calif., June 9, 2025 /PRNewswire/ -- Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of...
Mosanna Therapeutics secured $80 million in a series A round to develop MOS-118 as a treatment for the nearly 1 billion people globally with obstructive...
REDWOOD CITY, Calif., June 9, 2025 /PRNewswire/ -- Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of...
Track Mosanna and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Mosanna and other trending companies.